CodeBreak 300
04 May 2022
CodeBreak 300
NCT05198934
Sotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
Amgen
Cancer Type | Bowel & colon |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years to 100 years |
Sex | All |
Tumour Stream | - |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2022-04-29 |
Anticipated End Date | 2024-01-01 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Dr Timothy Price |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs